The United Arab Emirates has officially become the second nation globally, following the United States, to authorize Lipfendra, a once-daily oral medication designed to manage high levels of LDL cholesterol. Approved by the Emirates Drug Establishment (EDE), the treatment features the active ingredient enlicitide and is specifically aimed at adults struggling with elevated "bad" cholesterol, including those suffering from inherited conditions. This medical advancement provides doctors with a vital new tool to help patients lower their cardiovascular risks when lifestyle changes alone are insufficient.

While the introduction of this pill marks a significant step forward in pharmaceutical care, health authorities emphasize that it is not a substitute for a healthy lifestyle. The EDE stresses that the medication is intended to complement—not replace—a balanced diet and regular physical activity. Patients are strongly encouraged to consult with their healthcare providers to evaluate their unique medical history and risk factors before beginning treatment. By integrating this new therapeutic option with proactive wellness habits, the UAE aims to bolster patient health and streamline access to cutting-edge medical innovations.